Skip to main content
SpringerLink
Log in

Chemotherapy in the Management of Prostate Cancer

  • Chapter
  • First Online:
Principles and Practice of Urooncology

  • 1093 Accesses

Abstract

Less than a decade ago, metastatic castration-resistant prostate cancer (mCRPC ) was deemed to be a “chemoresistant” disease, with a poor prognosis. The landmark TAX327 trial, published in 2004, showed that a course of chemotherapy based on the taxane docetaxel could extend survival for men with mCRPC. Then, in 2010 it was reported that men with mCRPC who progressed during or after docetaxel could gain a further survival benefit from a second line of chemotherapy, based on another taxane, cabazitaxel .

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tannock IF, Osoba D, Stocker MF. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.

    Article  CAS  PubMed  Google Scholar 

  2. Winquist E, Waldron T, Berry S, et al. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the cancer care Ontario program in evidence-based care’s genitourinary cancer disease site group. BMC Cancer. 2006;6:112.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Basch EM, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tannock IF, de Wit R, Berry WR, et al. for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  CAS  PubMed  Google Scholar 

  5. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    Article  PubMed  Google Scholar 

  6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  CAS  PubMed  Google Scholar 

  7. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

    Article  CAS  PubMed  Google Scholar 

  8. Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5(2):119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010;73:68–91.

    Article  PubMed  Google Scholar 

  10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer. Version 3.2012. NCCN: Pennsylvania; 2012.

    Google Scholar 

  11. Loriot Y, Massard C, Gross-Goupil M, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer. 2010;46:1770–2.

    Article  CAS  PubMed  Google Scholar 

  12. Shimura T, Kitagawa M, Yamada T, et al. The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer. Onkologie. 2012;35:176–83.

    Article  CAS  PubMed  Google Scholar 

  13. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547–52.

    Article  CAS  PubMed  Google Scholar 

  14. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–30.

    Article  CAS  PubMed  Google Scholar 

  15. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24(9):2402–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. de Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol. 2010;(Suppl):abstract 9.

    Google Scholar 

  17. Bahl A, Masson S, Malik Z, et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). J Clin Oncol 2012;30(Suppl):abstract 44.

    Google Scholar 

  18. Sridhar SS, Winquist E, Hubay S, et al. Cabazitaxel early access program (EAP)—Canadian interim results: safety, QOL, and utility values in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol. 2012;23(Suppl 9):abstract 960.

    Google Scholar 

  19. Castellano D, Aparicio LMA, Esteban E, et al. Cabazitaxel for castration-resistant prostate cancer: safety data from the Spanish expanded access program. J Expert Opin Drug Safety. 2014;13:1165–73.

    Article  CAS  Google Scholar 

  20. de Bono J, Hardy-Bessard AC, Kim CS, et al. Phase III non-inferiority study of cabazitaxel 20 mg/m2 versus cabazitaxel 25 mg/m2 in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (PROSELICA). Proceedings of the ASCO, 2016.

    Google Scholar 

  21. Meisel A, von Felten S, Vogt DR, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016;56:93–100.

    Article  CAS  PubMed  Google Scholar 

  22. Omlin A, Sartor O, Rothermundt C, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitour Cancer. 2015;13:e205–8.

    Article  Google Scholar 

  23. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72:3457–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–9.

    Article  CAS  PubMed  Google Scholar 

  26. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is upregulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Antonarakis ES, Lu C, Wang H, et al. ARV7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA. 2015;1(5):582–91.

    Google Scholar 

  29. Nakazawa M, Lu C, Chen Y, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015;26:1859–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang T, Armstrong AJ. Clinical utility of circulating tumor cells in advanced prostate cancer. Curr Oncol Rep. 2016;18:3.

    Article  PubMed  Google Scholar 

  31. Jiang J, Huang H. Targeting the androgen receptor by taxol in castration resistant prostate cancer. Mol Cell Pharmacol. 2010;2:1–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992–8002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate. 2009;69:1579–85.

    Article  CAS  PubMed  Google Scholar 

  36. Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012. [Epub ahead of print].

    Google Scholar 

  37. Seruga B, Tannock IF. Chemotherapy-based treatment for castration- resistant prostate cancer. J Clin Oncol. 2011;29:3686–94.

    Article  CAS  PubMed  Google Scholar 

  38. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:12–23.

    Article  CAS  PubMed  Google Scholar 

  39. NCT00988208. Study to evaluate safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate-resistant prostate cancer (Mainsail). Celgene announces discontinue phase III MAINSAIL trial.

    Google Scholar 

  40. Quinn DI, Tangen CM, Hussain M, et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol. 2012;30(Suppl):[abstract 4511].

    Google Scholar 

  41. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double- blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol. 2010;28(Suppl):344s. [abstract LBA4511].

    Google Scholar 

  42. Tannock IF, Fizazi K, Ivanov S, et al. VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760–8.

    Article  CAS  PubMed  Google Scholar 

  43. Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740–7.

    Article  CAS  PubMed  Google Scholar 

  44. Araujo JC, Trudel GC, Armstrong AJ, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007;34:22–9.

    Article  CAS  PubMed  Google Scholar 

  46. Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65–71.

    Article  PubMed  Google Scholar 

  47. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol. 2000;31:406–14.

    Article  CAS  PubMed  Google Scholar 

  48. Furtado P, Lima MV, Nogueira C, et al. Review of small cell carcinomas of the prostate. Prostate Cancer. 2011;2011:543272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Isshiki S, Akakura K, Komiya A, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;167:512–5.

    Article  CAS  PubMed  Google Scholar 

  50. Ather MH, Abbas F, Faruqui N, et al. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2008;8:21.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Rigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther. 2008;7:659–69.

    Article  Google Scholar 

  52. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem. 2007;282:3571–83.

    Article  CAS  PubMed  Google Scholar 

  54. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. N Engl J Med. 2013;368:1314–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.

    Article  Google Scholar 

  57. Sweeney C, Chen Y-H, Carducci M, et al. Chemohormonal therapy in hormone-sensitive metastatic prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.

    Article  CAS  PubMed  Google Scholar 

  59. James ND, Sydes MR, Mason MD, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancer. 2016;387:1163–77.

    Article  CAS  Google Scholar 

  60. Vale CL, Burdett S, Tierney JF. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration- dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28(30):4562–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration- resistant prostate cancer: is there a clinical benefit? Urol Oncol. 2015;33(11):494.e15–20.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, American Hospital, Istanbul, Turkey

    Sevil Bavbek M.D.

Authors
  1. Sevil Bavbek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sevil Bavbek M.D. .

Editor information

Editors and Affiliations

  1. Chair and Professor, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit

  2. Chair and Professor, Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bavbek, S. (2017). Chemotherapy in the Management of Prostate Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation